P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
BACKGROUND
In this study we investigated whether the presence of p53 antibodies in sera before of during/after radiation therapy can predict increased survival in patients with non-small cell lung cancer.


METHODS
Sera from 67 patients with a histopathologically confirmed diagnosis of nonsmall cell lung cancer have been investigated using sandwich ELISA (Dianova, Hamburg, Germany). Sera was collected before or during/after radiation therapy.


RESULTS
Antibodies were detected in 18 (27%) patients. 46/67 (69%) of the sera had been taken before start of radiation therapy and the presence of p53 antibodies was a statistically significantly good prognostic factor in terms of increased survival (p = 0.025).


CONCLUSIONS
p53 antibodies in sera, before the start of radiation therapy, can predict increased survival after radiation treatment in patients with non-small cell lung cancer.
Bergqvist
M
M
Department of Oncology, Akademiska Hospital, University of Uppsala, Sweden.
Brattström
D
D
Larsson
A
A
Holmertz
J
J
Hesselius
P
P
Rosenberg
L
L
Wagenius
G
G
Brodin
O
O
D000230:Adenocarcinoma / Q000276:immunology / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000401:mortality / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D001323:Autoantibodies; D016159:Tumor Suppressor Protein p53